Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 29.2% in March

Assembly Biosciences, Inc. (NASDAQ:ASMBGet Free Report) was the target of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 42,600 shares, a decline of 29.2% from the March 15th total of 60,200 shares. Approximately 1.2% of the shares of the company are sold short. Based on an average daily volume of 29,900 shares, the days-to-cover ratio is presently 1.4 days.

Assembly Biosciences Trading Down 2.7 %

Shares of NASDAQ:ASMB opened at $14.65 on Friday. The stock has a 50 day moving average of $12.75 and a 200 day moving average of $10.80. The company has a market cap of $80.33 million, a PE ratio of -0.86 and a beta of 0.57. Assembly Biosciences has a 12-month low of $7.69 and a 12-month high of $20.04.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st. StockNews.com upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, April 5th.

Get Our Latest Stock Analysis on ASMB

Insider Buying and Selling at Assembly Biosciences

In other news, major shareholder Alexander Schornstein purchased 24,999 shares of the business’s stock in a transaction on Wednesday, January 17th. The stock was acquired at an average cost of $9.36 per share, for a total transaction of $233,990.64. Following the purchase, the insider now directly owns 655,357 shares in the company, valued at approximately $6,134,141.52. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders sold a total of 2,066 shares of company stock worth $26,924 in the last three months. 4.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Acuitas Investments LLC purchased a new position in Assembly Biosciences in the 4th quarter worth approximately $218,000. Renaissance Technologies LLC lifted its holdings in Assembly Biosciences by 52.1% in the 1st quarter. Renaissance Technologies LLC now owns 765,800 shares of the biopharmaceutical company’s stock worth $644,000 after purchasing an additional 262,416 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Assembly Biosciences by 4.4% in the 4th quarter. Vanguard Group Inc. now owns 2,339,088 shares of the biopharmaceutical company’s stock worth $1,918,000 after purchasing an additional 99,092 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in Assembly Biosciences by 123.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 123,772 shares of the biopharmaceutical company’s stock worth $255,000 after purchasing an additional 68,411 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Assembly Biosciences by 587.6% in the 4th quarter. Jane Street Group LLC now owns 76,961 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 65,768 shares in the last quarter. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences Company Profile

(Get Free Report)

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.

Further Reading

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.